Expanding the frontiers: IL-23 pathway in psoriasis and psoriatic arthritis

This live evening event will examine recent developments in the management of psoriasis and psoriatic arthritis. The event will begin with a presentation on the evolution of the psoriasis management landscape over the past 10 years. It will be followed by a panel discussion on the latest clinical trial data and real-world evidence in psoriasis and psoriatic arthritis, and how these data impact clinical practice. The audience is invited to ask questions and join this lively discussion.

If you are unable to attend the live broadcast, you will have the opportunity to watch theon-demand version once it is available.

Learning objectives

After this event, participants should be able to:

• Describe the benefit of biologics as early treatment for patients with moderate-to-severe psoriasis
• Analyse the safety and efficacy data from randomized clinical trials and real-world evidence for psoriasis treatment
• Identify special patient profiles and explain the optimal management of their disease

Faculty

• Alexander Egeberg (Denmark)
• Kilian Eyerich (Sweden)
• Chris Griffiths (UK)

Programme (All times are shown in CET)

17:30–17:35 Welcome and introduction
Kilian Eyerich 

17:35–17:50 Progress in psoriasis: a decade on
Chris Griffiths

17:50–18:25 Clinical dialogue: IL-23 pathway in psoriasis and psoriatic arthritis – interactive panel discussion 
Alexander Egeberg and Kilian Eyerich, moderated by Chris Griffiths 

18:25–18:30 Conclusion and close
Chris Griffiths